A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• The P-selectin/PSGL-1 pathway is crucial for initiating and propagating venous thrombosis.
• Leukocyte and platelet accumulation in thrombi is mediated by this pathway.
• Activated platelets and endothelium express P-selectin, binding to PSGL-1 on leukocytes.

Purpose of the Study:

• To develop a potent inhibitor of the P-selectin/PSGL-1 pathway.
• To assess the therapeutic potential of a novel glycomimetic, P-G6, for venous thrombosis.
• To evaluate the safety profile of P-G6 regarding hemostasis.

Main Methods:

• Development of a pegylated glycomimetic inhibitor (P-G6) targeting the N terminus of PSGL-1.
• In vitro assessment of P-G6's inhibition of platelet-monocyte and platelet-neutrophil aggregation.
• In vivo evaluation of P-G6 in a nonocclusive deep vein thrombosis model and microcirculation studies.

Main Results:

• P-G6 demonstrated potent inhibition of P-selectin/PSGL-1 interactions.
• In vitro studies showed P-G6 effectively inhibited platelet-leukocyte aggregation.
• In vivo administration of P-G6 reduced thrombus formation and leukocyte accumulation in deep vein thrombosis models without affecting hemostasis.

Conclusions:

• P-G6 is a potent inhibitor of the P-selectin/PSGL-1 pathway.
• P-G6 shows promise as a therapeutic agent for preventing venous thrombosis.
• The drug candidate P-G6 offers a potential treatment for venous thrombosis with a reduced risk of bleeding.